This activity has been designed to address the educational needs of institutional and community-based medical oncology clinicians and other clinicians who are involved in the management of patients with metastatic breast cancer (mBC).
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 1 credit
MOC types
No MOC
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Address:
- 523 Route 303
Pricing
97% of listed courses are free
34 of 35 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Communication & Shared Decision-Making
- Dermatology
- Gastroenterology
- General Pediatrics
- Hematology
- Medical Oncology
- Nephrology
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Psychotic Disorders
- Rheumatology
- Surgical Oncology
- Cross-Specialty
- GI & Liver
- Medical Subspecialties
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pathology & Lab
- Pediatrics
- Psychiatry
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedApr 17, 2026
-
Last day to claim creditApr 18, 2027 6 months left
-
Paradigm Medical Communications, LLC The Latest Updates on the Role of HER2-Low and HER2-Ultralow in Treatment Selection for Metastatic Breast Cancer
-
Paradigm Medical Communications, LLC Incorporating HER2-Low and HER2-Ultralow in Optimizing Treatment of mBC
-
Paradigm Medical Communications, LLC Expert Analysis of HER2-Low and HER2-Ultralow Updates to Pathology Practice
-
EfficientCME, CME Outfitters, LLC Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team
-
PRIME Education, Inc. (PRIME®) Scaling Excellence in HER2-Low and -Ultralow Breast Cancer: Real-World Strategies for Testing and Treatment Optimization
-
Learner’s Digest International (TM) Ultra-Low HER2 Breast Cancer
